28 August 2025 – Biophytis

Skip to content

Home
About Us
Longevity Platform
Bio101
- BIO101 in Sarcopenia
- BIO101 in Obesity
Biophytis Biopharmaceutical
Other Projects
Resources
- Posters & Publications
- Scientific Press Releases
Recruitment
Investors
Contact
EN
FR

Blog Category

August 28, 2025

Biophytis Receives EMA and Belgian Regulatory Approval to Initiate Phase 3 Sarcopenia Clinical Trial

Press Releases, Regulatory

/

28 August 2025

Addresses

Addresses

BIOPHYTIS France
Silver Innov’
54 rue Molière
94200 Ivry-Sur-Seine
FRANCE

Addresses

BIOPHYTIS USA
c/o NGIN
210 Broadway, Suite #201
Cambridge, MA 02139
USA

Addresses

BIOPHYTIS Brazil
CIETEC
Av. Prof. Lineu Prestes
2242 Cidade Universitária USP
05508-000 São Paulo
BRASIL

Contact

contact@biophytis.com +33 1 76 28 40 83

Investors

investors@biophytis.com

© Biophytis 2026.

All Rights Reserved.

Legal information

Webdesign by Ex Calibra

Home
About Us
Longevity Platform
Bio101
- BIO101 in Sarcopenia
- BIO101 in Obesity
Biophytis Biopharmaceutical
Other Projects
Resources
- Posters & Publications
- Scientific Press Releases
Recruitment
Investors
Contact
EN
FR

Home
About Us
Longevity Platform
Bio101
- BIO101 in Sarcopenia
- BIO101 in Obesity
Biophytis Biopharmaceutical
Other Projects
Resources
- Posters & Publications
- Scientific Press Releases
Recruitment
Investors
Contact
EN
FR